Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickshVIVO Regulatory News (HVO)

Share Price Information for hVIVO (HVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.90
Bid: 28.50
Ask: 29.30
Change: 0.00 (0.00%)
Spread: 0.80 (2.807%)
Open: 28.90
High: 28.90
Low: 28.90
Prev. Close: 28.90
HVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

30 Oct 2017 07:00

RNS Number : 8953U
hVIVO plc
30 October 2017
 

For immediate release 7.00am: 30 October 2017

 

HVIVO PLC

("hVIVO" or the "Company")

 

Directorate Change

 

Trevor Phillips to assume role of Executive Chairman

 

Experienced biopharmaceutical executive will work closely with existing management team to refine and focus strategy to drive the business forward

 

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical development capabilities, today announces the appointment of Dr Trevor Phillips as Executive Chairman, succeeding current Non-Executive Chairman, Jaime Ellertson who has held that position since June 2014. Jaime will remain on the board as a Non-Executive Director. Based in the US, Jaime is currently also CEO and Chairman of Everbridge Inc. (NASDAQ:EVBG).

 

Trevor will work closely with Kym Denny, CEO of hVIVO, to refine and focus the Company's strategy to drive the business forward. He has over thirty years' of experience in the pharmaceutical industry and has a proven track record in corporate development. He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc. Prior to this, he served as Chief Executive Officer and Chief Operating Officer at Critical Therapeutics Inc. and has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.).

 

Trevor was originally appointed a Non-Executive Director of hVIVO in June 2017 and will assume his new role on 13 November 2017.

 

Kym Denny, CEO of hVIVO, said:

"I am delighted that Trevor has accepted the role of Executive Chairman and I, as well as the rest of the management team, look forward to working closely with him. He has a wealth of experience in the sector, serving in a number of senior management roles at biopharmaceutical companies, including Vectura Group Plc, a company that is also focused on diseases that impact the airways and that has grown over time to become a constituent member of the FTSE 250. Trevor's expertise in operations and corporate development in the space will be invaluable as we seek to refine our strategy to drive revenue growth and build a robust and profitable business that is centred on our proprietary Pathomics platform.

 

I would like to thank Jaime for all his support and guidance as Non-Executive Chairman over the past three years. This has been a formative time for hVIVO as we have sought to strengthen the Company's position as a specialised centre of excellence for the clinical research and development of new therapies for respiratory and infectious diseases. We look forward to continuing to benefit from Jaime's counsel as a Non-Executive Director."

 

Speaking on his appointment as Executive Chairman of hVIVO, Dr Trevor Phillips commented:

"I am excited at this opportunity to work with the hVIVO team to drive the business forward. I believe the Pathomics platform that the company has developed, coupled with the Company's clinical expertise and know-how is a valuable and unique asset for those involved in the discovery and development of drugs for diseases that impact the airways and so enable precision therapies. I look forward to guiding the management team to ensure that the commercial potential of the platform and the business is realised so as to generate significant and sustainable shareholder value."

 

For further information please contact:

 

hVIVO plc

+44 207 756 1300

Kym Denny (Chief Executive Officer)

Graham Yeatman (Chief Financial & Business Officer)

Media Enquiries

Susan Flood

+1 919 710 9658

 

Numis Securities Limited

+44 207 260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)

James Black / Michael Burke (Corporate Broking)

FTI Consulting

Simon Conway / Victoria Foster Mitchell (UK)

+44 203 727 1000

 

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOADMMZGVNRGNZM
Date   Source Headline
27th Mar 20247:00 amRNSNotice of Results
22nd Mar 20243:03 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSHolding(s) in Company
15th Feb 20247:00 amRNSLong Term Incentive Plan / PDMR Notification
14th Feb 20241:14 pmRNSResult of Secondary Placing
14th Feb 20247:00 amRNSProposed Secondary Placing of Ordinary Shares
2nd Feb 202412:44 pmRNSHolding(s) in Company
30th Jan 20247:00 amRNSTrading update
8th Jan 20247:00 amRNSBroker change
2nd Jan 20247:00 amRNS£6.3m HRV contract signed with biotech client
13th Dec 20237:00 amRNS£16.8m RSV contract & Trading ahead of guidance
5th Oct 20237:00 amRNSPositive results from flu human challenge study
12th Sep 20237:00 amRNSInterim results
1st Sep 20237:00 amRNSExercise of Warrants
29th Aug 20237:00 amRNSPlans for a new larger state-of-the-art facility
24th Aug 20237:00 amRNSNotice of Results
26th Jul 20237:00 amRNSTrading update
25th Jul 20237:00 amRNSFlu B challenge model
28th Jun 20237:00 amRNShMPV human challenge model
14th Jun 20238:00 amRNSDirector dealings
23rd May 202312:36 pmRNSResult of AGM
28th Apr 20237:00 amRNSAnnual Report and Notice of AGM
26th Apr 20237:00 amRNSFDA Breakthrough and Fast Track for US biotech
25th Apr 20237:00 amRNSFinal results
19th Apr 20237:10 amRNSNotice of Results
6th Apr 20233:54 pmRNSHolding(s) in Company
3rd Apr 20237:00 amRNSPositive results from flu human challenge study
29th Mar 20237:00 amRNSPresentation at World Vaccine Congress
23rd Mar 20237:00 amRNSExercise of Options
16th Mar 20237:00 amRNSOmicron human challenge model update
6th Feb 20239:05 amRNSSecond Price Monitoring Extn
6th Feb 20239:00 amRNSPrice Monitoring Extension
6th Feb 20237:05 amRNSLong Term Incentive Plan / PDMR Notification
6th Feb 20237:00 amRNS£6.8m RSV human challenge contract signed
25th Jan 20239:06 amRNSSecond Price Monitoring Extn
25th Jan 20239:00 amRNSPrice Monitoring Extension
25th Jan 20237:00 amRNSTrading update
17th Jan 20237:00 amRNSEUR3.2m Venn contract with global pharma client
4th Jan 20234:40 pmRNSSecond Price Monitoring Extn
4th Jan 20234:35 pmRNSPrice Monitoring Extension
4th Jan 20237:00 amRNS£5.2m RSV contract and Notice of Trading update
3rd Jan 20234:40 pmRNSSecond Price Monitoring Extn
3rd Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20232:05 pmRNSSecond Price Monitoring Extn
3rd Jan 20232:00 pmRNSPrice Monitoring Extension
3rd Jan 202311:05 amRNSSecond Price Monitoring Extn
3rd Jan 202311:00 amRNSPrice Monitoring Extension
19th Dec 20227:00 amRNSImutex Phase I data published
17th Nov 20222:05 pmRNSSecond Price Monitoring Extn
17th Nov 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.